SAMSRITA LABS LIMITED

To, Date: 11.11.2026

BSE Limited, P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: 539267	National Stock Exchange of India Limited, Exchange Plaza, Bandra- Kurla Complex, Mumbai 400051 Symbol: SAMSRITA

Sub: Outcome of Board Meeting held on 11.11.2026 under Regulations 30 read with 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref : Company's Letter dated 03.11.2026

Unit: Samsrita Labs Limited

Dear Sir/Madam,

With reference to the above mentioned subject, this is to inform the Exchanges that the Board of Directors of Samsrita Labs Limited in its meeting held on Wednesday, 11.11.2026 at the registered office of the Company, inter-alia, considered and approved the following items:

1. Un-audited Standalone and Consolidated financial results for the quarter and half year ended September, 30, 2026 along with the Limited review reports. (enclosed)

The Board Meeting commenced at 3.30 p.m and concluded at 5.00 p.m

Thanking you.

Yours sincerely
For Samsrita Labs Limited

Maddukuri Gita Usha Rani

Digitally signed by Maddukuri Gita Usha Rani
Date: 2026.11.11 17:06:22 +05'30'

M. Gita usha Rani
Company Secretary & Compliance officer
M. No. A65602

Encl: As above

PART-I

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

[Amount in Lakhs.]

S.No	Particulars	Quarter ended			Half Year ended		Previous Year ended
		3 Months ended 30-09-2026	Corresponding 3 months ended in previous year 30-09-2025	Preceding 3 months ended 30-06-2026	Half year ended 30-09-2026	Half year ended 30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-	-	1.81
II	Other Income	-	-	-	-	-	3.15
III	Total Revenue (I+II)	-	-	-	-	-	4.96
IV	Expenses						
	Purchases	-	-	-	-	-	1.65
	Cost of Material Consumed	-	-	-	-	-	-
	Employee benefits expense	5.27	10.43	9.80	15.07	25.96	39.11
	Finance Cost	-	-	-	-	-	-
	Depreciation and Amortisation expense	0.29	0.03	0.12	0.41	0.06	0.14
	Other Expenses	6.05	483.04	21.55	27.60	495.14	832.66
	Total Expenses	11.61	493.50	31.47	43.08	521.16	873.56
V	Profit/(Loss) from before Exceptional items and tax (I-IV)	(11.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(11.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(11.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(11.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(11.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	(0.05) (0.05)	(2.17) (2.17)	(0.14) (0.14)	(0.19) (0.19)	(2.29) (2.29)	(4.25) (4.25)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each) 1) Basic	(0.05)	(2.17)	(0.14)	(0.19)	(2.29)	(4.25)
	2) Diluted	(0.05)	(2.17)	(0.14)	(0.19)	(2.29)	(4.25)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,274.97	2274.97	2,274.97	2,274.97	2274.97	2274.97

Notes:

1 The Un-Audited financial Results (Standalone & Consolidated) of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules thereunder, other accounting principles generally accepted in India and regulations issued by the Securities and Exchange Board of India ("SEBI").

2 The above Un-Audited financial results (Standalone & Consolidated) have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 11-11-2026.

3 The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.

4 The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison.

5 The Managing Director and Chief Financial Officer of the Company have certified in terms of Regulation 33(2)(a) of SEBI (LODR) Regulations, 2015 that the above financial results do not contain any false or misleading statements or figures and do not omit any material fact which make the statement and figures contained therein misleading.

Place : Hyderabad
Date : 11/11/2026

For SAMSRITA LABS LIMITED

K.Krishnam Raju
Chairman & Whole-time Director (DIN -00874650)

SAMSRITA LABS LIMITED

Standlone Statement of Assets and Liabilities

(Amount in Lakhs.)

	Particulars	Half Year Ended 30-09-2026 (Unaudited)	Year Ended 31-03-2026 (Audited)
	ASSETS		
1	**Non Current Assets**		
a	Property, Plant and Equipment	11.00	0.36
b	Capital Work In Progress	-	-
c	Investment Property	-	-
d	Goodwill	-	-
e	Other Intangible Assets	-	-
f	Intangible Assets under development	200.00	200.00
g	Biological assets other than bearer plants	-	-
h	Financial Assets	-	-
i	Investments in Associates	942.06	942.06
ii	Trade Receivables	-	-
iii	Loans	-	-
iv	Others	-	-
v	Loans	-	-
vi	Others	-	-
i	Deferred Tax Assets (net)	-	-
j	Other Non Current Assets	-	-
	Total Non Current Assets	**1,153.06**	**1,142.42**
2	**Current Assets**		
a	Inventories	-	-
b	Financial Assets	-	-
i	Investments	-	-
ii	Trade Receivables	0.96	1.96
iii	Cash and Cash Equivalents	100.29	162.88
iv	Bank balances other than above	-	-
v	Loans and Advances	-	-
vi	Other financial assets	-	-
c	Current Tax Assets (net)	-	-
d	Other Current Assets	100.28	89.65
	Total Current Assets	**201.53**	**254.49**
	Total Assets	**1,354.59**	**1,396.91**
	EQUITY AND LIABILITIES		
1	**Equity**		
a	Equity Share Capital	2,274.97	2,274.97
b	Other Equity	-	-
i	Share Warrants	-	-
ii	Reserves and Surplus	(1,184.17)	(1,141.09)
iii	Non-Controlling Interests	-	-
	Total - Equity	**1,090.79**	**1,133.88**
2	**Liabilities**		
	Non Current Liabilities		
a	Financial Liabilities	-	-
i	Borrowings	-	-
ii	Trade Payables	-	-
iii	Other Financial Liabilities	-	-
b	Provisions	9.24	9.24
c	Deferred Tax Liabilities (net)	-	-
d	Other Non Current Liabilities	-	-
	Total Non Current Liabilities	**9.24**	**9.24**
	Current Liabilities		
a	Financial Liabilities		
i	Borrowings	166.20	166.20
ii	Trade Payables	0.96	1.78
iii	Other Financial Liabilities	87.40	85.81
b			-
c	Provisions	-	-
d	Current Tax Liabilities (net)	-	-
	Total Current Liabilities	**254.56**	**253.79**
	Total - Equity and Liabilities	**1,354.59**	**1,396.91**

For SAMSRITA LABS LIMITED

SAMSRITA LABS LIMITED

Place: Hyderabad
Date : 11/11/2026

K.Krishnam Raju
Chairman & Whole-time Director (DIN 00874650)

SAMSRITA LABS LIMITED

STANDLONE STATEMENT OF CASH FLOWS

PARTICULARS	Half Year Ended September 30,2026	Year Ended 31st March,2026
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(43.08)	(868.60)
Adjustment for:		
Depreciation and Amortisation	0.41	0.14
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(42.67)	(868.46)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	1.00	207.03
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(10.64)	255.53
(Increase)/ Decrease in Intangible Assets	-	
(Increase)/ Decrease in other Financial Assets	-	-
(Increase)/ Decrease in Inventories	-	-
Increase /(Decrease) in Trade Payables	(0.82)	(1.69)
Increase/ (Decrease) in Other current liabilities	1.59	(16.36)
Increase/ (Decrease) in Current Provisions	-	(1.99)
Change in Working Capital	(8.87)	442.52
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances	-	-
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	-	-
Changes in non current assets and liabilities	-	-
Cash Generated From Operations	(51.54)	(425.94)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(51.54)	(425.94)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) in Property, Plant & Equipment / Intangible under development (net of depreciation)	(11.05)	-
Increase/ (Decrease) in Security Deposit	-	
(Increase) / Decrease in investment in subsidiary/associates	-	-
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Proceeds from sales of intangible assets under development	-	326
-Balance of Unclaimed Dividend	-	-
Net cash used in investing activities (B)	(11.05)	326
C.CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	339
Increase / (Decrease) in Borrowings	-	(76.48)
Interest paid	-	-
Net cash Flow from Financing Activities (C)	-	262.62
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents	-	-
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(62.60)	162.64
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	162.88	0.24
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	100.29	162.88

For and on behalf of the Board
for SAMSRITA LABS LIMITED

SAMSRITA LABS LIMITED

K.Krishnam Raju
Chairman & Whole-time Director (DIN -00874650)

Place: Hyderabad
Date: 11/11/2026

MGR & CO
CHARTERED ACCOUNTANTS

HYDERABAD OFF:
Flat No: 101, Suranjana Empire Estates,
Dwarakapuri Colony, Punjagutta, Hyderabad 500082

Independent Auditor's Review Report on unaudited Standalone Quarterly Financial Results of Samsrita Labs Limited (Formerly known as Dr Habeebullah Life Sciences Limited) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Samsrita Labs Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended September 30, 2026 and year-to-date results for the period April 01, 2026 to September 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation").

2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

MGR & CO FRN No: 012787S Chartered Accountants

HO : BHIMAVARAM: 24-3-11/201, Suma Sri Residency, Main Street, Sriramapuram, Bhimavaram, Andhra Pradesh -534202
Phone: 9676399599

BO : MUMBAI: AKT House, Plot No C1 B 4/32., Opp. Artist Village Busstand, Near Arenja Complex, Sec8, CBD Belapur, Mumbai-400614.
Email: camgr9@gmail.com

MGR & CO
CHARTERED ACCOUNTANTS

HYDERABAD OFF:
Flat No: 101, Suranjana Empire Estates,
Dwarakapuri Colony, Punjagutta, Hyderabad 500082

5. Emphasis of Matters

1. We draw attention to the **proposed investment** of up to ₹1,00,00,000 in S Labs Hygiene Care Private Limited through subscription to Compulsorily Convertible Preference Shares (CCPS), approved by the Board of Directors on 28th September 2026 and subsequently by the shareholders at the Extraordinary General Meeting held on 26th October 2026. The investment is expected to be undertaken during Q3 of FY 2026-27, subject to applicable terms and statutory requirements. Accordingly, the financial impact of the proposed investment, if any, will be reflected in the financial results of the subsequent quarter.

2. We draw attention to the approval accorded by the Board of Directors on 28th September 2026 and subsequently by the members on 26th October 2026 for the proposed material **related party transaction** involving the sale of goods to S Labs Hygiene Care Private Limited for an aggregate value not exceeding ₹25,00,00,000 during the period from 26th October 2026 to 25th October 2027, in the ordinary course of business and on an arm's length basis.

3. We draw attention to the approval accorded by the Board of Directors for availing an **unsecured loan** of up to ₹1,00,00,000 (Rupees One Crore only) from Mr Ravi Kanth Naga Pattabhi Chopperla, Non-Executive Director of the Company, carrying interest at 9% per annum. The said proposal was subsequently approved by the members of the Company at the Extraordinary General Meeting held on 26th October 2026. The loan is proposed to be availed in accordance with the applicable terms and statutory requirements.

   Our Conclusion is **not modified** in respect of this matter.

For MGR & CO
Chartered Accountants
FRN:012787S



M.G Rao
Partner
M.No.029893
UDIN: 26029893DTZBHZ2220.
Place: Hyderabad
Date: 11.11.2026

HO : BHIMAVARAM: 24-3-11/201, Suma Sri Residency, Main Street, Sriramapuram, Bhimavaram, Andhra Pradesh -534202
Phone: 9676399599

BO : MUMBAI: AKT House, Plot No C1 B 4/32., Opp. Artist Village Busstand, Near Arenja Complex, Sec8, CBD Belapur, Mumbai-400614.
Email: camgr9@gmail.com

(Amount in Lakhs.)

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

S.No	Particulars	Quarter ended			Half Year ended		Previous Year ended
		3 Months ended 30-09-2026	Corresponding 3 months ended in previous year 30-09-2025	Preceding 3 months ended 30-06-2026	Half year ended 30-09-2026	Half year ended 30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	-	-	-	-	1.81
II	Other Income	-	-	-	-	-	3.15
III	Total Revenue (I+II)	-	-	-	-	-	4.96
IV	Expenses						
	Purchases	-	-	-	-	-	1.65
	Cost of Material Consumed	-	-	-	-	-	-
	Employee benefits expense	5.27	10.43	9.80	15.07	25.96	39.11
	Depreciation and Amortisation expense	0.29	0.03	0.12	0.41	0.06	0.14
	Other Expenses	6.05	483.04	21.55	27.60	495.14	832.66
	Total Expenses	31.61	493.50	31.47	43.08	521.16	873.56
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(31.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(31.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(31.61)	(493.50)	(31.47)	(43.08)	(521.16)	(868.60)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Share of Profit (loss) of Associates and Joint ventures accounted for using equity method	(16.68)	35.73	12.60	(4.08)	(60.71)	52.55
XIV	Profit/ (Loss) for the period (IX+XII)	(28.29)	(454.77)	(18.87)	(47.16)	(460.45)	(816.05)
XV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVI	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(28.29)	(454.77)	(18.87)	(47.16)	(460.45)	(816.05)
XVII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	(0.12) (0.12)	(2.00) (2.00)	(0.08) (0.08)	(0.21) (0.21)	(2.02) (2.02)	(3.99) (3.99)
XVIII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-	-	-	-	-	
XIX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each) 1) Basic 2) Diluted	(0.12) (0.12)	(2.00) (2.00)	(0.08) (0.08)	(0.21) (0.21)	(2.02) (2.02)	(3.99) (3.99)
	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,274.97	2,274.97	2,274.97	2,274.97	2,274.97	2,274.97

Notes:

1 The Un-Audited Financial Results (Standalone & Consolidated) of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules thereunder, other accounting principles generally accepted in India and regulations issued by the Securities and Exchange Board of India ("SEBI").

2 The above Un-Audited financial results (Standalone & Consolidated) have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 11-11-2026.

3 The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.

4 The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison.

5 The Managing Director and Chief Financial Officer of the Company have certified in terms of Regulation 33(2)(a) of SEBI (LODR) Regulations, 2015 that the above financial results do not contain any false or misleading statements or figures and do not omit any material fact which make the statement and figures contained therein misleading.

Place : Hyderabad
Date : 11/11/2026

For SAMSRITA LABS LIMITED

K.Krishnam Raju
Chairman & Whole-time Director (DIN :00874630)

SAMSRITA LABS LIMITED

SAMSRITA LABS LIMITED

Consolidated Statement of Assets and Liabilities

(Amount in Lakhs.)

	Particulars	Half Year Ended 30-09-2026 (Unaudited)	Year Ended 31-03-2026 (Audited)
	ASSETS		
1	**Non Current Assets**		
a	Property, Plant and Equipment	11.00	0.36
b	Capital Work In Progress	-	-
c	Investment Property	-	-
d	Goodwill	-	-
e	Other Intangible Assets	-	-
f	Intangible Assets under development	200.00	200.00
g	Biological assets other than bearer plants	-	-
h	Financial Assets	-	-
i	Investments	979.47	983.55
ii	Trade Receivables	-	-
iii	Loans	-	-
iv	Others	-	
v	Loans	-	-
vi	Others	-	-
i	Deferred Tax Assets (net)	-	-
j	Other Non Current Assets	-	-
	Total Non Current Assets	**1,190.47**	**1,183.91**
2	**Current Assets**		
a	Inventories	-	-
b	Financial Assets	-	-
i	Investments	-	-
ii	Trade Receivables	0.96	1.95
iii	Cash and Cash Equivalents	100.29	162.88
iv	Bank balances other than above	-	-
v	Loans and Advances	-	-
vi	Other financial assets	-	-
c	Current Tax Assets (net)	-	-
d	Other Current Assets	100.28	89.65
	Total Current Assets	**201.53**	**254.49**
	Total Assets	**1,392.00**	**1,438.40**
	EQUITY AND LIABILITIES		
1	**Equity**		
a	Equity Share Capital	2,274.97	2,274.97
b	Other Equity	-	-
i	Share Warrants	-	-
ii	Reserves and Surplus	(1,146.77)	(1,099.61)
iii	Non-Controlling Interests	-	-
	Total - Equity	**1,128.20**	**1,175.36**
2	**Liabilities**		
	Non Current Liabilities		
a	Financial Liabilities	-	-
i	Borrowings	-	-
ii	Trade Payables	-	-
iii	Other Financial Liabilities	-	-
b	Provisions	9.24	9.24
c	Deferred Tax Liabilities (net)	-	-
d	Other Non Current Liabilities	-	-
	Total Non Current Liabilities	**9.24**	**9.24**
	Current Liabilities		
a	Financial Liabilities		
i	Borrowings	166.20	166.20
ii	Trade Payables	0.96	1.78
iii	Other Financial Liabilities	-	
b	Other Current Liabilities	87.40	85.81
c	Provisions	-	-
d	Current Tax Liabilities (net)	-	-
	Total Current Liabilities	**254.56**	**253.79**
	Total - Equity and Liabilities	**1,392.00**	**1,438.40**

For SAMSRITA LABS LIMITED

Place: Hyderabad
Date: 11/11/2026

K.Krishnam Raju
Chairman & Whole-time Director (DIN 00874850)

SAMSRITA LABS LIMITED

CONSOLIDATED STATEMENT OF CASH FLOWS

PARTICULARS	Half Year Ended September 30,2026	Year Ended 31st March,2026
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(43.08)	(868.60)
Adjustment for:		
Depreciation and Amortisation	0.41	0.14
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(42.67)	(868.46)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	1.00	207.03
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(10.64)	255.53
(Increase)/ Decrease in Intangible Assets	-	
(Increase)/ Decrease in other financial Assets	-	-
(Increase)/ Decrease in Inventories	-	-
Increase /(Decrease) in Trade Payables	(0.82)	(1.69)
Increase/ (Decrease) in Other current liabilities	1.59	(16.36)
Increase/ (Decrease) in Current Provisions	-	(1.99)
Change in Working Capital	(8.87)	442.52
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances	-	-
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	-	-
Changes in non current assets and liabilities	-	-
Cash Generated From Operations	(51.54)	(425.94)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(51.54)	(425.94)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) in Property, Plant & Equipment / Intangible under development (net of depreciation)	(11.05)	-
Increase/ (Decrease) in Security Deposit	-	
(Increase) / Decrease in investment in subsidiary/associates	-	-
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Proceeds from sales of intangible assets under development	-	326
-Balance of Unclaimed Dividend	-	-
Net cash used in Investing activities (B)	(11.05)	326
C.CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	339
Increase / (Decrease) in Borrowings	-	(76.48)
Interest paid	-	-
Net cash Flow from Financing Activities (C)	-	262.62
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents	-	-
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(62.60)	162.64
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	162.88	0.24
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	100.29	162.88

For and on behalf of the Board
for SAMSRITA LABS LIMITED

SAMSRITA LABS LIMITED

K.Krishnam Raju
Chairman & Whole-time Director (DIN -00874650)

Place: Hyderabad
Date: 11/11/2026

MGR & CO
CHARTERED ACCOUNTANTS

HYDERABAD OFF:
Flat No: 101, Suranjana Empire Estates,
Dwarakapuri Colony, Punjagutta, Hyderabad 500082

Independent Auditor's Review Report on unaudited Consolidated Quarterly Financial Results of Samsrita Labs Limited (Formerly known as Dr Habeebullah Life Sciences Limited) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Samsrita Labs Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended September 30, 2026 and year-to-date results for the period April 01, 2026 to September 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")

2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and



accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. The Statement includes the interim financial results of two associate companies, **Krisani Biosciences Private Limited**, whose interim financial results reflect **total loss** of **₹ 17,360** out of which the company's share is based on its ownership interest of **32.91% i.e ₹ 5,713.18** and **Qrops Advisory Services Private Limited,** whose interim financial results reflect **total loss of ₹ 58,08,289.95** out of which the company's share is based on its ownership interest of **28.62% i.e ₹ 16,62,332.58** for the quarter ended 30 September 2026, as considered in the Statement. These financial results have not been reviewed by us. The reports have been furnished to us by the management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these associates, is based solely on the financials provided by the management and the procedures performed by us as stated in paragraph 3 above.

5. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, ", Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures" Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

MGR & CO * FRN No: 012787S * Chartered Accountants

6. Emphasis of Matters

1. We draw attention to the **proposed investment** of up to ₹1,00,00,000 in S Labs Hygiene Care Private Limited through subscription to Compulsorily Convertible Preference Shares (CCPS), approved by the Board of Directors on 28th September 2026 and subsequently by the shareholders at the Extraordinary General Meeting held on 26th October 2026. The investment is expected to be undertaken during Q3 of FY 2026-27, subject to applicable terms and statutory requirements. Accordingly, the financial impact of the proposed investment, if any, will be reflected in the financial results of the subsequent quarter.

2. We draw attention to the approval accorded by the Board of Directors on 28th September 2026 and subsequently by the members on 26th October 2026 for the proposed material **related party transaction** involving the sale of goods to S Labs Hygiene Care Private Limited for an aggregate value not exceeding ₹25,00,00,000 during the period from 26th October 2026 to 25th October 2027, in the ordinary course of business and on an arm's length basis.

3. We draw attention to the approval accorded by the Board of Directors for availing an **unsecured loan** of up to ₹1,00,00,000 (Rupees One Crore only) from Mr. Ravi Kanth Naga Pattabhi Chopperla, Non-Executive Director of the Company, carrying interest at 9% per annum. The said proposal was subsequently approved by the members of the Company at the Extraordinary General Meeting held on 26th October 2026. The loan is proposed to be availed in accordance with the applicable terms and statutory requirements.

Our Conclusion is **not modified** in respect of this matter.

For MGR & CO
Chartered Accountants
FRN:012787S

M.G Rao
Partner
M.No.029893
UDIN: 26029893NBFUBG1673
Place: Hyderabad
Date: 11.11.2026